Trials Sponsors Conditions Drugs Pricing

Conditions

Pancreatic Cancer

Keywords

PancreasCancerPancreatic AdenocarcinomaMetastaticGlufosfamide

Outcome Measures

Primary Outcomes (1)

Overall Survival

Secondary Outcomes (7)

Objective tumor response rate
Duration of objective tumor response rate
Progression-free survival
6 month and 12 month survival
Serum CA 19-9
+2 more secondary outcomes

Interventions

GlufosfamideDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

At least 18 years of age
Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)

Sponsors & Collaborators

Threshold Pharmaceuticals
Industrylead
PPD Development, LP
Industrycollaborator

Study Sites (111)

Augusta Oncology Associates

Los Angeles, California, 90057, United States

Kenmar Research Institute

Los Angeles, California, 90057, United States

Mile High Oncology

Denver, Colorado, 80210, United States

Northwestern Connecticut Oncology - Hematology Associates

Torrington, Connecticut, 06790, United States

Palm Beach Institute of Hematology and Oncology

Boynton Beach, Florida, 33435, United States

Hematology/Oncology of the North Shore

Skokie, Illinois, 60076, United States

Fort Wayne Medical Oncology/Hem

MeSH Terms

Conditions

Pancreatic NeoplasmsNeoplasmsNeoplasm Metastasis

Interventions

beta-D-glucosylisophosphoramide mustard

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsDigestive System DiseasesPancreatic DiseasesEndocrine System DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

December 10, 2004

First Posted

December 10, 2004

Study Start

September 2004

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2007

Actual (reported)

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (111)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (111)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations